{"entity":{"id":"nct07628504","kind":"trial","name":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","aka":["STARTER"],"tldr":"A phase 3 trial of sacituzumab tirumotecan and capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting.","summary":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations. ClinicalTrials.gov record last updated 2026-06-05: not yet recruiting. Enrollment is planned at 420 participants. Primary completion is estimated at 2030-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab Tirumotecan (sac-TMT), Capecitabine. Registered primary measures: Disease-Free Survival (DFS).","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07628504","url":"https://clinicaltrials.gov/study/NCT07628504"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy"],"targets":["trop2"],"drugs":["sacituzumab-tirumotecan","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-06-05: not yet recruiting. Enrollment is planned at 420 participants. Primary completion is estimated at 2030-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07628504","phase":"3","setting":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","sponsor":"Fudan University","participation":[{"nct":"NCT07628504","source":"https://clinicaltrials.gov/study/NCT07628504","fetchedAt":"2026-10-07T16:55:51.217Z","studySha256":"1d817f94358e2455d74dad7010f2213f845a2139cfe15e604a28243e2c36bd71","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-06-05","leadSponsor":"Fudan University","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":420,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2026-05-18","startedType":"estimated","enrolled":420,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07628504/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}